FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Novartis Gets Another Facility OKd for Pluvicto

[ Price : $8.95]

FDA approves Novartis Radioligand Therapy manufacturing facility in Millburn, NJ to manufacture prostate cancer therapy Pluvicto, ...

DTC Research Raises Concern on Endpoints in Cancer Ads

[ Price : $8.95]

New research on drug direct-to-consumer television advertising finds that viewers misinterpreted certain oncology clinical trial e...

Priority Review Voucher Awarded to Pharming Tech

[ Price : $8.95]

Federal Register notice: FDA issues a priority review voucher to Pharming Technologies that was related to its rare pediatric dise...

Priority Review Voucher Awarded to Pharming Tech

[ Price : $8.95]

Federal Register notice: FDA issues a priority review voucher to Pharming Technologies that was related to its rare pediatric dise...

FDA Updates Alert on O&M Halyard N95 Masks

[ Price : $8.95]

FDA provides further clarification about a safety alert issued earlier this month that recommended against the use of certain surg...

Guide on Radiation Syndrome Drug Development

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Acute Radiation Syndrome: Developing Drugs for Prevention a...

10 Observations in Lupin FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with 10 observations from a recent inspection at a Lupin drug manufacturing facility in Pithampur, I...

Sarepta Comments on Golodirsen PSG

[ Price : $8.95]

Sarepta raises several points for FDA consideration on an agency draft product-specific guidance for golodirsen.

GE Healthcares Carescape Patient Monitor Cleared

[ Price : $8.95]

FDA clears a GE HealthCare 510(k) for its Carescape Canvas patient monitoring platform for precise, flexible patient care.

FDA Describes New QSAR Model

[ Price : $8.95]

An FDA online post describes research creating new quantitative structure-activity relationship models to predict blood-brain barr...